Padayachy, Laura
Ntallis, Sotirios G.
Halazonetis, Thanos D.
Funding for this research was provided by:
European Commission (788681)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (212666)
Article History
Received: 25 December 2023
Accepted: 28 March 2024
First Online: 2 April 2024
Competing interests
: T.D.H. is a founder and shareholder of FoRx Therapeutics AG. The remaining authors declare no competing interests.